Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the efficacy and tolerability of CETP INhibition with AnacEtrapib) trial

Journal of Clinical Lipidology

Volumn 9, Issue 1, 2015, Pages 65-71

  Brinton, Eliot A ^a   Kher, Uma ^b   Shah, Sukrut ^b   Cannon, Christopher P ^c   Davidson, Michael ^d   Gotto, Antonio M ^e   Ashraf, Tanya B ^b   Sisk, Christine McCrary ^b   Dansky, Hayes ^b   Mitchel, Yale ^b   Barter, Philip ^f   DEFINE Investigators, ^g  

^a Utah Foundation for Biomedical Research   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d RADIANT RESEARCH   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

^g NONE

Author keywords

Anacetrapib; Cholesteryl ester transfer; High density lipoproteins; Low density lipoproteins; Plasma triglycerides; Protein inhibitors

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; CETP PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPID; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIAC PATIENT; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; CORONARY DISEASE; LEAST SQUARE ANALYSIS; METABOLISM; MIDDLE AGED; PLACEBO EFFECT; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEAST-SQUARES ANALYSIS; LIPIDS; MALE; MIDDLE AGED; OXAZOLIDINONES; PLACEBO EFFECT; TREATMENT OUTCOME;

EID: 84927631045     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2014.10.005     Document Type: Article

References (21)

1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
2. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610.
3. Catapano AL, Reiner Ž, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217:1-44.
4. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301-1310.
5. Gotto AM. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. Am Heart J. 2002;144:S33-S42.
6. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins - an idea whose time for testing is coming, Part I. Circulation. 2001;104:2376-2383.
7. Krishna R, Anderson MS, Bergman AJ, et al. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 2007;370:1907-1914.
8. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and co-administered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-360.
9. Barter PJ, Caulfield M, Eriksson M, et al, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
10. Cannon CP, Shah S, Dansky HM, et al, for the DEFINE Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-2415.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterols in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
12. Davidson M, Liu SX, Barter P, et al. Measurement of LDL-C after treatment with the CETP inhibitor, anacetrapib. J Lipid Res. 2013;54:467-472.
13. Cannon CP, Dansky HM, Davidson M, et al, for the DEFINE investigators. Design of the DEFINE trial: Determining the EFficacy and Tolerability of CETP INhibition with AnacEtrapib. Am Heart J. 2009;158:513-519.
14. Krishna R, Bergman AJ, Jin B, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84:679-683.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
16. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med. 1990;322:1700-1707.
17. Haffner SM, Lehto S, Ronnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
18. Heart Disease and Stroke Statistics - 2005 Update. Dallas Texas: American Heart Association; 2005.
19. Marcovina SM, Albers JJ, Wijsmant E, Zhang Z, Chapman NH, Kennedy H. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res. 1996;37:2569-2585.
20. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res. 1993;34:1255-1274.
21. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA. 2011;306:2099-2109.